[Docetaxel and ovarian cancer]

Area of Science:

• Oncology
• Pharmacology

Background:

• Docetaxel demonstrates clinical activity in advanced ovarian cancer, including platinum-refractory and paclitaxel-resistant cases.
• In vitro studies indicate no complete cross-resistance between docetaxel and paclitaxel.

Purpose of the Study:

• To evaluate docetaxel as a single agent and in combination chemotherapy for advanced ovarian cancer.
• To compare the efficacy and safety of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line treatment.

Main Methods:

• Phase I-II trials assessed docetaxel-platinum doublets.
• A Phase III trial compared docetaxel-carboplatin with paclitaxel-carboplatin in first-line treatment for ovarian cancer stages IC to IV.

Main Results:

• Docetaxel as a single agent achieved a 30% overall response rate in previously treated patients.
• Docetaxel-carboplatin demonstrated feasibility and high effectiveness, with a more favorable safety profile (reduced neurotoxicity) compared to docetaxel-cisplatin.
• Preliminary Phase III results support docetaxel-carboplatin over paclitaxel-carboplatin due to lower neurosensory toxicity.

Conclusions:

• Docetaxel is active in advanced ovarian cancer, even in resistant cases.
• Docetaxel-carboplatin is a feasible and effective first-line chemotherapy option for ovarian cancer, offering improved neurotoxicity profile compared to paclitaxel-carboplatin.
• Further data on survival and quality of life are needed to fully establish the relative merits of docetaxel-carboplatin and paclitaxel-carboplatin.